CDK4/6i plus AI or fulvestrant shows similar clinical benefit in HR+ HER2- MBC
Two drugs linked to longer survival than palbociclib in breast cancer
This retrospective single-center analysis of 341 patients with HR+/HER2− MBC found that palbociclib, abemaciclib, and dalpiciclib combined w…
In a real-world analysis, two CDK4/6 inhibitors showed longer survival times than palbociclib for metastatic breast cancer patients.
Imlunestrant shows OS benefit in ESR1-mutated advanced breast cancer in Phase III trial
A New Pill Combo Helps Women with Advanced Breast Cancer Live Longer
A Phase III RCT of 874 endocrine-pretreated ER+/HER2- advanced breast cancer patients found imlunestrant monotherapy improved median OS vers…
A new pill combo helps women with advanced breast cancer live longer and delays the need for harsh chemotherapy.